Human Papillomavirus

Cervical Cancer Vaccines

Three vaccines are available for the prevention of HPV-associated dysplasias and neoplasia, including cervical, vulvar, vaginal, and anal cancer; genital warts (condylomata acuminata); and precancerous genital lesions. Human papillomavirus vaccine, nonavalent (Gardasil 9), Human papillomavirus vaccine, quadrivalent (Gardasil), Human papillomavirus vaccine, bivalent (Cervarix). Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Safety of HPV vaccine during pregnancy, currently there are two inactive recombinant HPV vaccines available. Although the National Advisory Committee on Immunization recommends not using the vaccine in pregnant women, inadvertent exposures during pregnancy do occur. Recommended schedule for administering HPV vaccine, dosage of vaccine, vaccine series, minimum intervals of doses of vaccines should be monitored. Contraindications may include History of a severe (anaphylactic) reaction to a vaccine component or following a previous dose and pregnancy. Advancement in HPV vaccines: Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers.